Pegylated IL‐10 induces cancer immunity: The surprising role of IL‐10 as a potent inducer of IFN‐γ‐mediated CD8+ T cell cytotoxicity
The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Abstract
Recently, the development of several strategies based on immunotherapy has raised hopes for a more promising way to treat cancer patients. Here, we describe how interleukin (IL)‐10, a seemingly unlikely candidate, stimulates the immune system in a particularly efficacious way. IL‐10, an omnipotent anti‐inflammatory cytokine, delivers an equally potent immune stimulation in the context of CD8+ T cells and tumor immunity. By activation of tumor‐resident, tumor‐specific CD8+ T cells, pegylated IL‐10 can induce rejection of large and metastasizing tumors in mice. Here, we summarize the mechanisms of action of IL‐10, the reasons why the mechanisms may be crucial for the treatment of cancer patients, and the rationale for applying pegylated IL‐10 in the clinic.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Interleukin-10 and the Interleukin-10 Receptor
Moore, K. W., de Waal Malefyt, R., Coffman, R. L., & O'Garra, A. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.683 · Cited by 6,737
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,545
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,972
Brahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,961
IL-10 inhibits cytokine production by activated macrophages
Fiorentino, D. F., Zlotnik, A., Mosmann, T. R., Howard, M., & O’Garra, A. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.11.3815 · Cited by 2,888
Cancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603
de Waal Malefyt, R., Haanen, J., Spits, H., Roncarolo, M. G., te Velde, A., Figdor, C., Johnson, K., Kastelein, R., Yssel, H., & de Vries, J. E. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.4.915 · Cited by 1,930
Cited by
Current status of interleukin-10 and regulatory T-cells in cancer
Dennis, K. L., Blatner, N. R., Gounari, F., & Khazaie, K. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000006 · Cited by 289
“Unau Health | Lippincott Williams & Wilk expectation, protective roles for IL-10 in cancer are emerging that stimulate a fresh look at the functions of this cytokine and of its cellular sources [17].”
BackgroundCytokines in CAR T Cell–Associated Neurotoxicity
Gust, J., Ponce, R., Liles, W. C., Garden, G. A., & Turtle, C. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.577027 · Cited by 264
T lymphocyte subsets in cancer immunity: Friends or foes
Chraa, D., Naim, A., Olive, D., & Badou, A. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.mr0318-097r · Cited by 172
Serum IL-10 Predicts Worse Outcome in Cancer Patients: A Meta-Analysis
Zhao, S., Wu, D., Wu, P., Wang, Z., & Huang, J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0139598 · Cited by 164
IL-10-producing T cells and their dual functions
Bedke, T., Muscate, F., Soukou, S., Gagliani, N., & Huber, S. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101335 · Cited by 152
Regulatory T‐cell heterogeneity and the cancer immune response
Ward‐Hartstonge, K. A., & Kemp, R. A. (2017) · Clinical & Translational Immunology · doi:10.1038/cti.2017.43 · Cited by 122
Inflammation and cancer: Till death tears them apart
Raposo, T. P., Beirão, B. C. B., Pang, L. Y., QUEIROGA, F. L., & Argyle, D. J. (2015) · The Veterinary Journal · doi:10.1016/j.tvjl.2015.04.015 · Cited by 132
A Survey on the Role of Interleukin-10 in Breast Cancer: A Narrative.
Sheikhpour, E., Noorbakhsh, P., Foroughi, E., Farahnak, S., Nasiri, R., & Neámatzadeh, H. (2018) · Europe PMC (PubMed Central) · Cited by 111
The role of interleukin 10 in human papilloma virus infection and progression to cervical carcinoma
Berti, F. C. B., Pereira, A. P. L., Cebinelli, G. C. M., Trugilo, K. P., & de Oliveira, K. B. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.03.002 · Cited by 118
Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review
Li, Y., Zhang, C., Jiang, A., Lin, A., Liu, Z., Cheng, X., Wang, W., Cheng, Q., Zhang, J., Wei, T., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05104-y · Cited by 105
Cytokine-based Cancer Immunotherapy: Challenges and Opportunities for IL-10
Rallis, K. S., Corrigan, A. E., Dadah, H., George, A. M., Keshwara, S. M., Sideris, M. C., & Szabados, B. E. (2021) · Anticancer Research · doi:10.21873/anticanres.15110 · Cited by 92
Engineered IL-10 variants elicit potent immunomodulatory effects at low ligand doses
Gorby, C., Sotolongo Bellón, J., Wilmes, S., Warda, W., Pohler, E., Fyfe, P. K., Cozzani, A., Ferrand, C., Walter, M. R., Mitra, S., et al. (2020) · Science Signaling · doi:10.1126/scisignal.abc0653 · Cited by 83
Manipulating IL-10 signalling blockade for better immunotherapy
Ni, G., Wang, T., Walton, S. F., Zhu, B., Chen, S., Wu, X., Wang, Y., Wei, M. Q., & Liu, X. (2015) · Cellular Immunology · doi:10.1016/j.cellimm.2014.12.012 · Cited by 71
Targeting interleukin-10 signalling for cancer immunotherapy, a promising and complicated task
Ni, G., Zhang, L., Yang, X., Li, H., Ma, B., Walton, S. F., Wu, X., Yuan, J., Wang, T., & Liu, X. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1717185 · Cited by 64
Regulator Versus Effector Paradigm: Interleukin-10 as Indicator of the Switching Response
Mingomataj, E., & Bakiri, A. H. (2015) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-015-8514-7 · Cited by 59
Interleukin-10: A double-edged sword in breast cancer
Chang, C., Lam, H. Y. P., Hsu, H., & Jiang, S. (2021) · Tzu Chi Medical Journal · doi:10.4103/tcmj.tcmj_162_20 · Cited by 53
Rallis, K. S., Corrigan, A. E., Dadah, H., Stanislovas, J., Zamani, P., Makker, S., Szabados, B. E., & Sideris, M. C. (2022) · Future Oncology · doi:10.2217/fon-2022-0063 · Cited by 50
T-cell Expression of IL10 Is Essential for Tumor Immune Surveillance in the Small Intestine
Dennis, K. L., Saadalla, A., Blatner, N. R., Wang, S., Venkateswaran, V., Gounari, F., Cheroutre, H., Weaver, C. T., Roers, A., Egilmez, N. K., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0169 · Cited by 45
Immune cell interplay in colorectal cancer prognosis
Norton, S. E., Ward-Hartstonge, K. A., Taylor, E. S., & Kemp, R. A. (2015) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v7.i10.221 · Cited by 40
Li, X., Lü, P., Li, B., Zhang, W., Yang, R., Chu, Y., & Luo, K. (2017) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.03.003 · Cited by 43
Pasqual-Melo, G., Sagwal, S. K., Freund, E., Gandhirajan, R. K., Frey, B., von Woedtke, T., Gaipl, U. S., & Bekeschus, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041379 · Cited by 39
Butt, O. H., Zhou, A. Y., Ances, B. M., DiPersio, J. F., & Ghobadi, A. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1110647 · Cited by 33
Ward‐Hartstonge, K. A., McCall, J. L., McCulloch, T. R., Kamps, A.-K., Girardin, A., Cretney, E., Munro, F. M., & Kemp, R. A. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1951-1 · Cited by 28
Chen, S., Wang, X., Wu, X., Wei, M. Q., Zhang, B., Liu, X., & Wang, Y. (2014) · Cellular Immunology · doi:10.1016/j.cellimm.2014.06.002 · Cited by 28
Radziejewska, I., Borzym‐Κluczyk, M., & Leszczyńska, K. (2020) · Biomedical Reports · doi:10.3892/br.2020.1395 · Cited by 27
Lipid phosphate phosphatase-2 promotes tumor growth through increased c-Myc expression
Tang, X., Cromwell, C. R., Liu, R., Godbout, R., Hubbard, B. P., McMullen, T. P. W., & Brindley, D. N. (2022) · Theranostics · doi:10.7150/thno.66230 · Cited by 23
IL-10 in cancer: Just a classical immunosuppressive factor or also an immunostimulating one?
Berti, F. C. B., & de Oliveira, K. B. (2018) · AIMS Allergy and Immunology · doi:10.3934/allergy.2018.2.88 · Cited by 25
Wang, S., Wang, J., Ma, R., Yang, S., Fan, T., Cao, J., Wang, Y., Ma, W., Yang, W., Wang, F., et al. (2020) · Molecular Immunology · doi:10.1016/j.molimm.2020.03.001 · Cited by 21
Chen, M. (2020) · International Journal of Ophthalmology · doi:10.18240/ijo.2020.04.11 · Cited by 19
Pharmacogenomic and epigenomic approaches to untangle the enigma of IL-10 blockade in oncology
Elemam, N. M., Mekky, R. Y., Rashid, G., Braoudaki, M., & Youness, R. A. (2024) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2023.26 · Cited by 19
Tao, Y., Xiao, J., Li, Y., & Zou, A. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s552449 · Cited by 16
Ma, Q., Chen, J., & Zhao, J. (2020) · Immunologic Research · doi:10.1007/s12026-020-09120-0 · Cited by 16
A unique CD8+ T lymphocyte signature in pediatric type 1 diabetes
Hamel, Y., Mauvais, F., Pham, H., Kratzer, R., Marchi, C., Barilleau, É., Waeckel-Énée, E., Arnoux, J., Hartemann, A., Cordier, C., et al. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.06.003 · Cited by 16
Composition and plasticity of triple‐negative breast carcinoma‐infiltrating regulatory T cells
Cai, B., Ma, P., Ding, P., Sun, D., Bu, Q., & Zhang, J. (2019) · Apmis · doi:10.1111/apm.13022 · Cited by 13
Therapy with CD4+CD25+ T regulatory cells – should we be afraid of cancer?
Gliwiński, M., Piotrowska, M., Iwaszkiewicz‐Grześ, D., Urban‐Wójciuk, Z., & Trzonkowski, P. (2019) · Współczesna Onkologia · doi:10.5114/wo.2019.84110 · Cited by 13
IL-10 driven memory T cell survival and Tfh differentiation promote HIV persistencePreprint
Ribeiro, S. P., Aïd, M., Dupuy, F. P., Chan, C. N., Hultquist, J. F., Delage, C., Moysi, E., Kulpa, D. A., Li, L., Xu, X., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.26.432955 · Cited by 14
Qiu, H., Hu, X., Gao, L., Chen, L., Chen, J., Yuan, J., Huang, C., Xu, X., & Yang, J. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.08.036 · Cited by 12
Aberrant Peripheral Immune Function in a Good Syndrome Patient
Chen, X., Zhang, J.-X., Shang, W., Xie, W., Jin, S.-X., & Wang, F. (2018) · Journal of Immunology Research · doi:10.1155/2018/6212410 · Cited by 11
Murillo, N., Lasso, P., Urueña, C. P., Pardo-Rodriguez, D., Ballesteros-Ramírez, R., Betancourt, G., Rojas, L., Cala, M. P., & Fiorentino, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612972 · Cited by 10
Pašvenskaitė, A., Liutkevičienė, R., Gedvilaitė, G., Vilkevičiūtė, A., Liutkevičius, V., & Uloza, V. (2021) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20241 · Cited by 9
PEGylated IL-10: Clinical Development in Cancer Immunotherapy, Where to Go?
Sebold, B. C., Ni, G., Li, J., Li, H., Liu, X., & Wang, T. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01355-4 · Cited by 9
Shmeleva, E. V., Boag, S. E., Murali, S., Bennaceur, K., Das, R., Egred, M., Purcell, I. F., Edwards, R., Todryk, S. M., & Spyridopoulos, I. (2015) · Immunity Inflammation and Disease · doi:10.1002/iid3.49 · Cited by 10
Aslam, A., Refaat, B., Almaimani, R. A., Obaid, A. A., Mujalli, A., Farrash, W. F., Elzubier, M., Idris, S., Salaka, A. S., Almalki, A. H., et al. (2025) · Discover Oncology · doi:10.1007/s12672-025-02452-z · Cited by 6
Certain BCG-reactive responses are associated with bladder cancer prognosis
Shan, G. L., Tang, T., Qian, H., & Xia, Y. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2127-y · Cited by 5
Chang, J., Zhang, W., Lin, G.-Y., Tong, D., Zhu, D. Y., Zhao, J., Yu, Q., Huang, D., & Li, W. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s275636 · Cited by 2
Shin, I. S., Kim, M. J., Rahman, M. H., Kim, C.-S., & Kim, K. (2025) · Molecular & Cellular Toxicology · doi:10.1007/s13273-025-00554-x · Cited by 1
IL-12 induced modulation of tumor derived myeloid cell inflammatory responsiveness.
Mitchell, C. (2014) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/991
Systemic Onco-sphere: Host Adaptive Immune System
Saw, P. E., & Song, E. (2023) · Springer eBooks · doi:10.1007/978-981-99-1183-7_20
Role of CD169 macrophages in cellular adaptive immune responses
Mauvais, F. (2016) · theses.fr (ABES) · doi:10.70675/a63cfe0cza36bz4b48z8a34zf880c078dc68
Shiban, E., Krauß, P., Schaller, T., Konietzko, I., Mögele, T., Jungbäck, N., Mielke, D., Märkl, B., Kahl, K.-H., Mielewczyk, Z., et al. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251389740
Devi-Marulkar, P. (2015) · theses.fr (ABES) · doi:10.70675/1afef94czc6daz4936zb0d3z44f75d1762b1
Chraa, D. (2019) · theses.fr (ABES) · doi:10.70675/8ad0de1ezeb55z4983z9084z94cc8799b353
Targeting histamine H4 receptor improves anti-tumoral response in a murine model of breast cancer
Vázquez, R., Saibene, P., Boix, M. E., Maio, M., Salamone, G. V., Balboa, L., & Vermeulen, M. E. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1770957
Yang, X., Liang, S., Wang, P., Huang, W., Song, K., Yu, M., & Gong, Z. (2026) · Discover Oncology · doi:10.1007/s12672-026-05442-x
Anti-proliferative and cytotoxic effects of CBD and CBDA in human colorectal cancer
Tasker, C. (2019) · Nottingham ePrints (University of Nottingham)
Structure-activity relationship analysis of Parapoxvirus Interleukin-10 proteins
Naqash, A. (2024) · Otago University Research Archive (University of Otago)
Metadata
- Authors
- Mumm, J. B., & Oft, M.
- Affiliations
- ARMO Biosciences Redwood City CA USA
- Corresponding author
- Oft, Martin
- Venue
- BioEssays
- Publisher
- Wiley
- Published
- 2013-05-13
- Volume
- 35
- Issue
- 7
- Pages
- 623-631
- ISSN
- 0265-9247 (ISSN-L)
- 1521-1878
- OpenAlex
- W2166586868
- Cited by
- 53
- References
- 81
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 2 · 2023: 3 · 2022: 3 · 2021: 4 · 2020: 9 · 2019: 4 · 2018: 5 · 2017: 5 · 2016: 1 · 2015: 8 · 2014: 2 · 2013: 1
- FWCI
- 0.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- BioEssays (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- IL-10, cancer immunotherapy, CD8+ T cells, antitumor immunity, tumor rejection, metastasis, anti-inflammatory cytokines, immunostimulation
- MeSH terms
- Animals, Disease Models, Animal, Humans, Immunotherapy, Interferon-gamma, Neoplasms, Polyethylene Glycols, Interleukin-10, CD8-Positive T-Lymphocytes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.